According to the group, these efforts include the preparation of comprehensive marketing collateral, establishing a secure data room, selecting the right licensing advisors to assist in global out-licensing for Complex Regional Pain Syndrome (CRPS) and depressive disorders.
Specialty pharmaceutical company iX Biopharma has released updates on two of its key strategic growth drivers: Wafermine, sublingual ketamine wafers; and iXB 401, sublingual semaglutide wafers.
On the back of the group’s termination of its licensing agreement with Seelos Therapeutics earlier this year, iX Biopharma says in a Sept 16 bourse filing that it has made “significant strides” in advancing Wafermine’s out-licensing efforts.
